Luke Walker
Technik-/Wissenschafts-/F&E-Leiter bei HARPOON THERAPEUTICS, INC.
Vermögen: 796 204 $ am 30.04.2024
Aktive Positionen von Luke Walker
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
HARPOON THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 03.10.2022 | - |
ZENTALIS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 29.05.2024 | - |
Independent Dir/Board Member | 29.05.2024 | - |
Karriereverlauf von Luke Walker
Ehemalige bekannte Positionen von Luke Walker
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CASCADIAN THERAPEUTICS INC (USA) | Technik-/Wissenschafts-/F&E-Leiter | - | 09.03.2018 |
SEAGEN INC. | Corporate Officer/Principal | - | - |
Ausbildung von Luke Walker
University of Oklahoma | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Cascadian Therapeutics LLC
Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Börse
- Insiders
- Luke Walker
- Erfahrung